Total Number of Pages in This Submission

3-15-07

PTO/SB/21 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

64348(41925)

| er the Paperwork Reduction Act of 1995, no persons are required to |                        | Office; U.S. DEPARTMENT OF COMMERCE<br>n unless it displays a valid OMB control number. |
|--|------------------------|---|
|  | Application Number     | 10/553,731-Conf. #4727  |
| TRANSMITTAL  | Filing Date            | October 18, 2005  |
| FORM   | First Named Inventor   | Christian Hubschwerlen  |
|  | Art Unit               | N/A   |
| (to be used for all correspondence after initial filing)           | Examiner Name          | Not Yet Assigned  |
| Total Number of Reges in This Submission                           | Attorney Docket Number | 64249(41025)  |

| ENCLOSURES (Check all that apply)      |   |   |          |  |  |  |
|--|---|---|----------|--|--|--|
| Fee Transr                             | mittal Form                                 | Drawing(s)  |          | After Allowance Communication to TC                            |  |  |
| Fee                                    | Attached                                    | Licensing-related Papers                                |          | Appeal Communication to Board of Appeals and Interferences     |  |  |
| Amendmer                               | nt/Reply                                    | Petition  |          | Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |  |  |
| After                                  | Final .                                     | Petition to Convert to a Provisional Application        |          | Proprietary Information  |  |  |
| Affida                                 | avits/declaration(s)                        | Power of Attorney, Revocati<br>Change of Correspondence |          | Status Letter  |  |  |
| Extension                              | of Time Request                             | Terminal Disclaimer                                     |          | X Other Enclosure(s) (please Identify below):                  |  |  |
| Express At                             | pandonment Request                          | Request for Refund                                      |          | Return Receipt Postcard  |  |  |
| x Information                          | n Disclosure Statement                      | CD, Number of CD(s)                                     |          |  |  |  |
| Certified Copy of Priority Document(s) |   | Landscape Table on                                      | CD       |  |  |  |
|  | issing Parts/<br>Application                | Remarks   |          |  |  |  |
|  | y to Missing Parts under<br>FR 1.52 or 1.53 |   |          |  |  |  |
|  |   |   |          |  |  |  |
|  |   |   |          |  |  |  |
| •                                      | SIGNATI                                     | JRE OF APPLICANT, ATTOR                                 | RNEY, OR | AGENT  |  |  |
| EDWARDS ANGELL PALMER & DODGE LLP      |   |   |          |  |  |  |
| Signature                              | Signature                                   |   |          |  |  |  |
| Printed name                           | Peter F. Corless                            |   |          |  |  |  |
| Date                                   | March 13, 2007                              |   | Reg. No. | 33,860   |  |  |

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV888715545US in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on March 13, 2007
Date

| Jusan m Ou                         | llon                    |
|------------------------------------|-------------------------|
| Signatu                            | re                      |
| Susan Dil                          | lon                     |
| Typed or printed name of per       | son signing Certificate |
|                                    | (617) 439-4444          |
| Registration Number, if applicable | Telephone Number        |

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (42 References) (2 pages) Information Disclosure Statement (2 pages)

Transmittal (1 page)



Docket No.: 64348(41925)

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Christian Hubschwerlen et al.

Application No.: 10/553,731

Filed: October 18, 2005 Art Unit: N/A

For: NOVEL COMPOUNDS HAVING AN

ANTIBACTERIAL ACTIVITY

**Examiner: Not Yet Assigned** 

Confirmation No.: 4727

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "Documents Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicants submit herewith a copy of the International Search Report of the corresponding International Application.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64348(41925).

Dated: March 13, 2007

Respectfully submitted,

Peter F. Corless

Registration No.: 33,860

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMP posterior. Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2 Sheet 1

| Complete if Known      |                        |  |  |  |
|------------------------|------------------------|--|--|--|
| Application Number     | 10/553,731-Conf. #4727 |  |  |  |
| Filing Date            | October 18, 2005       |  |  |  |
| First Named Inventor   | Christian Hubschwerlen |  |  |  |
| Art Unit               | N/A                    |  |  |  |
| Examiner Name          | Not Yet Assigned       |  |  |  |
| Attorney Docket Number | 64348(41925)           |  |  |  |

|           | U.S. PATENT DOCUMENTS |   |            |                             |                |  |  |
|-----------|-----------------------|---|------------|-----------------------------|----------------|--|--|
| Examiner  | Cite                  | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant |            |                             |                |  |  |
| Initials* | No.1                  | Number-Kind Code <sup>2</sup> ( if known)                     | MM-DD-YYYY | Applicant of Cited Document | Figures Appear |  |  |
|           | AA                    | US-3,184,462  | 05/18/1965 | Scarborough et al.          |                |  |  |
|           | AB                    | US-5,250,544  | 10/05/1993 | Lavielle et al.             |                |  |  |
|           | AC                    | US-5,747,502  | 05/05/1998 | Hanaoka et al.              |                |  |  |
|           | AD                    | US-6,046,206  | 04/04/2000 | Pamukcu et al.              |                |  |  |

|                       |              | FOREI   | GN PATENT                         | DOCUMENTS   |   |    |
|-----------------------|--------------|---|-----------------------------------|---|---|----|
| Examiner<br>Initials* | Cite<br>No.1 | Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> ) | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document          | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T⁵ |
|                       | ВА           | WO 96/39145 A1  | 12/12/1996                        | Rhone-Poulenc Rorer<br>Pharmaceuticals Inc.                 |   |    |
|                       | вв           | WO 99/10442 A1  | 01/14/1999                        | Zeneca Limited  |   |    |
|                       | вс           | WO 99/48461 A2  | 09/30/1999                        | Department of the Army                                      |   |    |
|                       | BD           | WO 00/78748 A1  | 12/28/2000                        | Smithkline Beecham P.L.C.                                   |   |    |
|                       | BE           | WO 01/07432 A2  | 02/01/2001                        | SMithkline Beecham P.L.C.                                   |   |    |
|                       | BF           | WO 01/10842 A2  | 02/15/2001                        | Millennium Pharmaceuticals, Inc.                            |   |    |
|                       | BG           | WO 01/46150 A2  | 06/28/2001                        | Glaxo Group Limited   |   |    |
|                       | вн           | WO 02/08224 A1  | 01/31/2002                        | Smithkline Beecham P.L.C.                                   |   |    |
|                       | ВІ           | WO 02/40474 A2  | 05/23/2002                        | Aventis Pharma S.A.   |   |    |
|                       | BJ           | WO 02/056882 A1   | 07/25/2002                        | Smithkline Beecham P.L.C.                                   |   |    |
|                       | вк           | WO 02/072572 A1   | 09/19/2002                        | Aventis Pharma S.A.   |   |    |
|                       | BL           | WO 03/064421 A1   | 08/07/2003                        | Glaxo Group Limited   |   |    |
|                       | вм           | WO 03/087098 A1   | 10/23/2003                        | Smithkline Beecham P.L.C.                                   |   | Г  |
|                       | BN           | WO 2004/002992 A1   | 01/08/2004                        | Glaxo Group Limited   |   |    |
|                       | во           | WO 2004/035569 A2   | 04/29/2004                        | Morphochem Aktiengesellschaft<br>Für Kombinatorische Chemie |   |    |
|                       | BP           | WO 2004/058144 A2   | 07/15/2004                        | Glaxo Group Limited   |   |    |
|                       | BQ           | WO 2006/021448 A1   | 03/02/2006                        | Morphochem Aktiengesellschaft<br>Für Kombinatorische Chemie |   | Г  |
|                       | BR           | JP 61200544 (w/abstract)  | 09/05/1986                        | Toyo Ink Mfg. Co.   |   | Г  |
|                       | BS           | EP 0 042781 B1 (w/abstract)   | 03/06/1985                        | Pharmuka Laboratories                                       |   | Г  |
|                       | ВТ           | EP 0 264 883 A2   | 04/27/1988                        | Banyu Pharmaceutical Co., Ltd.                              |   |    |
|                       | BU           | EP 0 486 022 B1   | 05/20/1992                        | Eisai Co., Ltd.   |   |    |
|                       | BV           | EP 0 737 670 B1 (w/abstract)  | 10/16/1996                        | Adir et Compagnie   |   |    |
|                       | ВW           | DE 102 47 233 A1 (w/abstract)   | 06/17/2004                        | Morphochem Aktiengesellschaft<br>Für Kombinatorische Chemie |   |    |
|                       | вх           | DE 102 56 405 A1 (w/abstract)   | 06/17/2004                        | Morphochem Aktiengesellschaft<br>Für Kombinatorische Chemie |   |    |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Interest of the triangle of the triangle of the triangle of the serial number of the patent document, by the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document, by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

| Examiner  | <br>Date       |  |
|-----------|----------------|--|
| Signature | <br>Considered |  |

596561

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO |                                   |      | · · · · · · · · · · · · · · · · · · · | Complete if Known      |                        |  |
|------------------------------|-----------------------------------|------|---------------------------------------|------------------------|------------------------|--|
|                              |                                   |      |                                       | Application Number     | 10/553,731-Conf. #4727 |  |
| 11                           | NFORMATION                        | N DI | SCLOSURE                              | Filing Date            | October 18, 2005       |  |
| 5                            | STATEMENT BY APPLICANT            |      |                                       | First Named Inventor   | Christian Hubschwerlen |  |
|                              |                                   |      |                                       | Art Unit               | N/A                    |  |
|                              | (Use as many sheets as necessary) |      | Examiner Name                         | Not Yet Assigned       |                        |  |
| Sheet                        | 2                                 | of   | 2                                     | Attorney Docket Number | 64348(41925)           |  |

|                      |              | NON PATENT LITERATURE DOCUMENTS  |    |
|----------------------|--------------|--|----|
| Examiner<br>Initials | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T² |
|                      | CA           | Chemical Abstract – Wei t al.; "A practical procedure for multisubstituted .betanaphthols and their derivatives" Tetrahedron, 59(34), 2003, pp. 6621-6625.   |    |
|                      | СВ           | Chemical Abstract – Harayama et al.; "Novel synthesis of naphthobenzazepines from N-bromobenzylnaphthylamines by regioselective C-H activation utilizing the intramolecular coordination of an amine to Pd"; Synlett, (8), 2003, pp. 1141-1144.  |    |
|                      | CC           | Chemical Abstract – Nagy et al.; "Theoretical and Experimental Study on Ion-Pair Formation and partitioning of organic Salts in Octano/Water and Dichloromethane/Water Systems"; Journal of the America Chemical Society; 122 (28), 2000, pp. 6583-6593.   |    |
|                      | CD           | Chemical Abstract – Moehrle et al.; "1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds"; Zeitschrift Fuer Naturforschung, B: Chemical Sciences; 53(7), 1998, pp. 742-752.   |    |
|                      | CE           | Chemical Abstract – Mathe-Allainmat et al.; "Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melantonin Receptors"; Journal of Medicinal Chemistry; 39 (16), 1996, pp. 3089-3095.   |    |
|                      | CF           | Chemical Abstract – Iwasaki et al.; "Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl) naphthalene Lignans"; Journal of Medicinal Chemistry, 39(14), 1996, pp. 2696-2704.  |    |
|                      | CG           | Chemical Abstract – Zhang et al.; "Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral Sulfides in chiral micelles"; Chinese Journal of Chemistry, (1), 1990, pp. 89-96.  |    |
|                      | СН           | Chemical Abstract – Smidrkal, Jan; "Synthesis of fagoronine"; Collection of Czechoslovak Chemical Communications; 53(12), 1998, pp. 3184-3192.   |    |
|                      | CI           | Chemical Abstract – Fleischhacker et al.; "Heterocyclic fuesed naphthalene systems from thebaine. 1"; Liebigs Annalen Der Chemie, (5), 1983, pp. 844-851.  |    |
|                      | Cl           | Chemical Abstract – Budzikiewicz et al.; "Vincetene, a benzopyrroloisoquinoline alkaloid, from Cynanchum vincetoxicum (L.) Pers. (Asclepiadaceae)"; Liebigs Annalen Der Chemie (8), 1979, pp. 1212-1231.   |    |
|                      | CK           | Chemical Abstract – Frost et al.; "Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9-trimethylphenaleno [1,2-b] furan-7-one"; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry; (19), 1973, pp. 3159-2169. |    |
|                      | CL           | Chemical Abstract – Jorgensen et al.; "Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine"; Journal of Medicinal Chemistry, 14(11), 1971, pp. 1023-1026.  |    |
|                      | СМ           | Chemical Abstract – Kasturi et al.; "Reactions of tetrahalo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone with tetralones and naphthols: pathway to the condensates"; Journal of the Chemical Society [Section] C: Organic, (9), 1970, pp. 1257-1259.   |    |
|                      | CN           | Chemical Abstract – Harada et al.; "Structure of pristimerin, a quinonoid triterpene"; Tetrahedron Letters, 1962, pp. 603-607.   |    |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Examiner  | Date       |
|-----------|------------|
| Signature | Considered |
|           |            |

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.